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Background: Red yeast rice (RYR) is a fermented product used as a food supplement to promote blood circulation
and lower blood cholesterol levels in eastern Asia. Interestingly, monacolin K is the most active compound in RYR
that proved to inhibit HMG-CoA reductase in the cholesterol biosynthesis pathway.
Methods: The hypocholesterolemic effects of oral administration of Thai RYR, produced by fermentation of Thai
glutinous rice (Oryza sativa L. var. Niaw San-pah-tawng) with Monascus purpureus CMU 002U, were determined in
normal and hypercholesterolemic rats. The rats were divided into six groups, and fed two different kinds of diet.
Groups I-II, normal rats fed with a normal diet (SP-diet), were treated with distilled water (SP-control) and 2.0 g/kg/
day of RYR extract (SP-2 g). In Groups III-VI, the rats were rendered hypercholesterolemic by feeding them a high fat
and cholesterol diet (HFC-diet), and were treated with distilled water (HFC-control), 1.0 g/kg/day (HFC-1 g), 2.0 g/
kg/day (HFC-2 g) of RYR extract, and 5.0 mg/kg/day of rosuvastatin (HFC-rosuvastatin) for 30 days, respectively.
Results: The RYR extract significantly decreased the concentrations of serum total cholesterol and low density
lipoprotein cholesterol (LDL-C), atherosclerotic index, LDL-C/HDL-C ratio and hepatic cholesterol levels in both
HFC-1 g and HFC-2 g groups (p < 0.05) as compared with the HFC-control group, and with no significant change in
high density lipoprotein cholesterol (HDL-C) concentrations among all six groups. The reduction of serum TC and
LDL-C also paralleled the observed changes in mRNA expressions of the genes involved in cholesterol biosynthesis
and homeostasis in the liver. The hypercholesterolemic rats treated with RYR extract were significantly higher in
LDLR and HMGR expression, but lower in CYP7A1 expression when compared to the untreated hypercholesterolemic
rats (HFC-control) (p < 0.05). The hepatic injuries in hypercholesterolemic rats were also obviously alleviated by RYR
extract.
Conclusions: The extract of Thai RYR possessed potent hypocholesterolemic and anti-atherogenic activities in
diet-induced hypercholesterolemic rats. The possible mechanism involving cholesterol-lowering potential of the
extract might contribute to its ability to increase LDL-C endocytosis in hepatocyte and to competitively inhibit
HMG-CoA reductase, a key enzyme for cholesterol biosynthesis in liver.
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Hypercholesterolemia is one of metabolic syndromes char-
acterized by the high level of plasma cholesterol. Incidence
of hypercholesterolemia is a major public health problem
and it continues to increase at an alarming rate. It can sig-
nificantly increase the risk of developing cardiovascular
diseases (CVDs), including atherosclerosis which is the
most common cause of morbidity and mortality worldwide
[1], accounting for almost 17 million deaths annually, and
is still most likely to be the main cause of death in the fu-
ture [2]. Hypercholesterolemia could be classified as either
familial hypercholesterolemia or acquired hypercholester-
olemia. Familial hypercholesterolemia is caused by specific
genetic abnormalities, especially the mutation of genes
encoding LDL receptor in both hepatic and extrahepatic
tissues. As a consequence, the level of plasma LDL-C is
extremely and constantly high leading to the early develop-
ment of heart disease [3]. In addition to CVDs, familial
hypercholesterolemia also leads to many other complica-
tions such as xanthomas, xanthelasmas, and obesity [4]. In
contrast to familial hypercholesterolemia, acquired hyper-
cholesterolemia or diet-induced hypercholesterolemia is
not inherited. It is characterized by the increased levels of
LDL-C as well as decreased levels of HDL-C. This latter
type of hypercholesterolemia is more common than the
former [5].
The dramatically increase incidence of non-inherited
hypercholesterolemia could be attributed to environ-
mental factors such as obesity and dietary factors. Foods
that contain high saturated fat and cholesterol are be-
lieved to be the most important factor of hypercholester-
olemias [6]. In addition, clinical studies have shown that
a high cholesterol diet and high levels of lipoproteins,
particularly LDL-C, in serum, can notably disturb the
cholesterol metabolism in the liver, and may also lead to
the development of hepatic steatosis formation or non-
alcoholic fatty liver disease (NAFLD) [7]. However, the
relationship between cholesterol and low density lipo-
proteins has been a concern for many years, due to its
potential to cause CVDs. Therefore, this issue needs to
be resolved urgently. The prevention of CVDs can be
addressed in several ways, for example by increasing
HDL-C or decreasing total cholesterol and LDL-C in-
take, associated with eating healthy food [8,9]. Addition-
ally, the use of cholesterol lowering drugs, such as
statins, is the most common and widely used method in
hypercholesterolemia treatment [10]. However, the un-
affordable price and side effects of these drugs make the
discovery of more effective and safer alternative products
to lower serum cholesterol much more attractive.
Red yeast rice (RYR), a fermented product of yeast
(Monascus purpureus) in rice, has been recognized as
early as 800 A.D., during the Tang Dynasty in China
[11]. It has a long history as being used as a preservativeand a natural dye for foods. It has also been used as medi-
cine for treating digestive disorder and promoting blood
circulation in some Asian countries [12]. Monacolin K,
(also known under the names mevinolin or lovastatin) is
the major compound occurring in the secondary metabo-
lites of RYR metabolism. It acts as 3-hydroxy-3-methyl-
glutaryl-CoA reductase (HMG-CoA reductase) inhibitor
[13]. Its ability to inhibit cholesterol biosynthesis in the
hepatic cells is due to its competitive inhibitory effect
upon HMG-CoA reductase activity [14,15]. In addition to
monakolin K, RYR also contains many substances, for in-
stances, fatty acid, palmitic acid, linoleic acid, oleic acid
and stearic acid. Those substances have been postulated
as the key regulators for serum cholesterol homeostasis
[11,16]. Many studies have succeeded in lowering serum
cholesterol levels in various species, including: chickens,
rabbits, rats, hamsters and humans [17-19]. In this study,
we investigated whether Thai RYR, Thai glutinous rice
(Oryza sativa L. var. Niaw San-pah-tawng) fermented by
Monascus purpureus CMU 002U, had the potential to
lower the serum cholesterol and hepatic cholesterol levels
of the diet-induced hypercholesterolemic rats. The mRNA
expressions of key enzymes responsible for cholesterol
biosynthesis and homeostasis, were determined, as was
the lipid deposition of the liver. These effects offer a direct
comparison between rats fed with a standard diet and rats
fed with a high-fat cholesterol diet.
Methods
Red yeast rice preparation and extraction
Thai glutinous rice, fermented with Monascus purpureus
CMU 002U (Red Yeast Rice), was formulated in the ‘Ex-
cellence in Sustainable Development of Biological Re-
source Laboratory’, Chiang Mai University, Chiang Mai,
Thailand. A step by step preparation of the red yeast rice
was executed, following a precise method developed by
Chairote et al. [20]. At the end of cultivation, the prod-
uct was dried at 65°C for 6 hours, and then ground in
order to obtain an extract from the dried red yeast rice.
One hundred grams of rice powder was soaked in
1,000 ml of 70% ethanol for a period of 24 hours. The
extract was then filtered, to remove the residue, and
evaporated using a vacuum rotary evaporator, in order
to obtain the crude extract. The red yeast rice crude ex-
tract was then lyophilized and stored at -20°C, until fur-
ther required. The residue was suspended in distilled
water, and previously verified doses were accumulated
for future experimentation.
Animals
Male and female Wistar rats (Rattus norvegicus) were pur-
chased from the ‘National Laboratory Animals Center’; a
department of Mahidol University based at its Salaya cam-
pus, in the province of Nakhon Pathom, Thailand. The
Table 1 Nutrition components of SP-diet and HFC-diet
(weight %) [23]
Ingredients SP-diet HFC-diet
SP diet 100.0 68.0
- Carbohydrate 46.5 31.62
- Crude protein 24.0 16.32
- Crude lipid 4.5 3.06
- Crude fiber 5.0 3.4
- Crude ash 10.0 6.8
- Moisture 10.0 6.8
- Palm oil - 12.5
- Lard - 12.5
- Cholesterol - 5.0
- Cholic acid - 2.0
Total energy (kcal/100 g) 318.0 416.2
The nutrition components are expressed as g/100 g of dry weight diet.
SP-diet: standard pellet diet, HFC-diet: high fat and cholesterol diet.
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controlled room having 12 hourly light and dark cycles, at
temperatures between 24-26°C and a relative humidity of
55-60%. The rats were offered food and water ad libitum.
These animal studies were approved by the Animal Care
and Ethics Committee of the Biology Department, Faculty
of Science, Chiang Mai University, Thailand. Food intake
was recorded daily, with body weight also being recorded
weekly.
Acute toxicity study
To evaluate the safety of the red yeast rice extract used
in this study, an acute toxicity test was initially con-
ducted on female rats weighing between 100 and 120 g.
This study was carried out as per the set guidelines of
the Organization for Economic Co-operation and Devel-
opment (OECD) [21]. The RYR extract used in this
study was safe, up to a dosage level of 5000 mg/kg, p.o.
Neither adverse effects on body weight and behaviors
nor mortality was detected in any rats throughout the
14 day observation period.
Diet and hypercholesterolemia induction
Four-week-old male rats weighing between 80 and 100 g
were used in this study. Wistar rats were chosen as the
experimental models since researches on hyperlipidemia
and hypercholesterolemia have been studied extensively
in this species. To induce hypercholesterolemia, after
acclimatization comprising 7 days of a standard pellet
diet (SP-diet), Thirty-two rats were switched to a modi-
fied high-fat content cholesterol diet (HFC-diet), as pre-
viously described by Kitamori et al. [22] for 45 days. The
HFC-diet contained 68% standard diet (containing 3.06%
fat), 12.5% palm oil, 12.5% lard, 5% cholesterol and 2%
cholic acid. The nutritional components of the SP-diet
and HFC-diet are summarized in Table 1.
Experimental design
The rats were randomly assigned to six groups of 8 rats
each and orally treated with RYR extract and rosuvastatin
for 30 days according to the following regimes: Group I)
SP-control: SP-dieted rats treated with distilled water at a
volume of 2.0 ml/day. Group II) SP-2 g: SP-dieted rats
treated with an RYR extract at a dose of 2.0 g/kg/day.
Group III) HFC-control: HFC-dieted rats treated with dis-
tilled water at a volume of 2.0 ml/day. Group IV) HFC-
1 g: HFC-dieted rats treated with RYR extract at a dose of
1.0 g/kg/day. Group V) HFC-2 g: HFC-dieted rats treated
with RYR extract at a dose of 2.0 g/kg/day, and Group VI)
HFC-rosuvastatin: HFC-dieted rats treated with rosuvasta-
tin at a dose of 5.0 mg/kg/day. Rats in groups I-II were
counted as “normocholesterolemic rats”, while those in
groups III-VI were counted as “hypercholesterolemic rats”.
The doses of RYR extract used in this study were basedupon doses reported in previous studies [23,24]. At the
end of the experimental period, all rats were sacrificed with
diethyl ether. Blood samples were collected by cardiac
puncture technique and prepared for serum biochemical
assay. Vital organs (liver, heart, brain and kidneys) were
immediately removed, cleaned and weighed. Portions of
liver were fixed in Bouin’s solution for histopathological
examination. For the liver mRNA determination, the liver
portion was kept in TRIZOL reagent (Sigma-Aldrich Co.
LLC, USA) then stored at -20°C, until needed. The rest of
liver portion was freshly kept at -20°C for determination of
liver lipid accumulation.
Serum biochemical assay
The sera were separated from the blood by centrifugation
at 3500 rpm for 10 minutes. The total cholesterol (TC),
high density lipoprotein cholesterol (HDL-C) and low
density lipoprotein cholesterol (LDL-C) were determined
by using automated photometric systems, and with the
cooperation of the ‘Medical Technology Clinic’, Faculty
of Associated Medical Sciences, Chiang Mai University,
Thailand.
Both the atherosclerotic index (AI) and the LDL-C/HDL-
C ratio were calculated, using the following formulae: AI =
(TC-HDL-C)/HDL-C and LDL-C/HDL-C ratio = LDL-C/
HDL-C [25].
Hepatic mRNA expressions and Real-time PCR analysis
Total RNA was extracted from the stored frozen liver tis-
sues using an innuPREP RNA Mini Kit (Analytik Jena, Life
Science, Jena, Germany) according to the manufacturer’s
instructions. The cDNA was synthesized using protocol
described by a Thermo Scientific RevertAid Reverse Tran-
scriptase kit (Thermo Fisher Scientific, Waltham, MA,
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time-PCR, using a THUNDERBIRD SYBR qPCR Mix
(Toyobo, Life Science, Osaka, Japan), and an Illumina
Eco Real-Time PCR Instrument (Illumina, San Diego,
CA, USA). The cycle condition was: 5 minutes at 95°C,
followed by 45 cycles of incubation at 95°C for 30 minutes,
61°C for 30 seconds and, finally, 72°C for 20 seconds. The
sequences of the primers used in this study were designed
for rat 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-
CoA reductase) gene [GenBank No.: X55286], low-density
lipoprotein receptor (LDL receptor) gene [GenBank
No.: X13722], cholesterol 7 alpha-hydroxylase (CYP7
A1) gene [GenBank No.: NM_012942], and glyceraldehyde-
3-phosphate dehydogenase (GAPDH) [GenBank No.: NM_
017008], as follows: HMG-CoA reductase forward 5-
GGTGGTGGGACCAACCTTCT-3, reverse 5-CACGCCC
CTTG AAC ACCTA-3: LDL receptor forward 5-CAGCC
GATGCATTCCTGACT-3, reverse 5-AGTTCATCCGAG
CCATTTTCA-3:CYP7A1 forward 5-CAAGTCAAGTGTC
CCCCTCT AGA-3, reverse 5-ACTCAATATCATGTAGT
GGTGGCAAA-3, and GAPDH forward 5-TGCCAAGT
ATG ATGACATCAAGAAG-3, reverse 5-AGCCCAGGA
TGCCCTTTAGT-3 [26]. The results were analyzed using
software provided by the Eco Real-Time PCR System.
Differences in mRNA expression were calculated using the
2ΔΔct method, after normalizing to a GAPDH expression
[27].
Liver lipid extraction and determination
Lipids from livers were extracted using the Folch method
[28]. One gram of tissue was ground in 20 ml of chloro-
form and methanol (2:1 v/v), and then sonicated for 30 -
minutes at room temperature. The aqueous layer was
aspirated and discarded, and the chloroform layer was
then evaporated until the residue was completely dry. The
dried lipid layer was then dissolved with isopropyl alcohol
containing 10% Triton-X100, and used to determine the
TC concentration using commercial enzymatic kits, which
had the same serum biochemical assay.
Histopathological analysis
Histopathological analysis was conducted following the
method of Buncharoen et al. [29]. The fixed liver tissuesTable 2 Effect of RYR extract on growth parameter and liver
Treatments groups Body weight gain (g/30 days) Food intake (g
SP-control 77.50 ± 10.00a 20.69 ± 1.47b
SP-2 g 83.88 ± 7.85a 21.23 ± 2.57b
HFC-control 105.00 ± 17.56a 16.23 ± 2.00a
HFC-1 g 95.00 ± 17.32a 16.63 ± 2.46a
HFC-2 g 103.75 ± 18.08a 18.72 ± 1.89ab
HFC-rosuvastatin 101.43 ± 35.08a 17.83 ± 2.36ab
Each value is the mean ± SD (n = 8). Values with different superscript letters (a,b,c)were dehydrated by progressively increased concentra-
tions of ethanol, then passed through a xylene solution
to clear the ethanol, and finally embedded in paraffin.
Paraffin sections were then sliced into 6 μm thick by a
rotary microtome. The tissue sections were stained with
hematoxylin and eosin (H&E), and examined under a
light microscope.
Statistical analysis
The results were expressed by mean ± standard deviation
(SD). Group means were compared using one-way analysis
of variance (ANOVA), and the significance level was
calculated using the Tukey HSD test. Values of p < 0.05
were considered to indicate statistical significance. All
data were analyzed using SPSS 21.0 for Windows (SPSS
Inc., Chicago, IL, USA).
Results
Acute toxicity study
Rats which have received an extract of red yeast rice at
the dose of 5,000 mg/kg body weight did not exhibit any
clinical signs of toxicity, changes in behavior, food or
water consumption, or body weight, or death, immedi-
ately after oral administration and during the experi-
mental period. There were no significant differences in
body weight and food intake, and there were no histo-
logical alterations of the liver, heart, brain and kidneys in
treated groups, when compared to the control group
(data not shown). The extract could therefore, be con-
sidered to be safe.
Effect of RYR administration on growth parameters
and liver weight
As shown in Table 2, no significant difference in body weight
gain was observed among all six groups. In addition, the
daily food intake of hypercholesterolemic rats in HFC-
control and HFC-1 g groups was significantly lower than
those in the SP-groups (p < 0.05).
The liver weights of hypercholesterolemic rats in all
groups (HFC-groups) were significantly higher than those
of normocholesterolemic rats (SP- groups) and HFC-
control group showed the highest value of liver weigh. Ad-
ministration of RYR extract at doses of 1.0 g/kg/day andweight
/rat/day) Liver weight (g) Relative liver weight (g/100 g BW)
10.70 ± 0.66a 2.53 ± 0.10b
10.83 ± 0.73a 2.50 ± 0.21b
22.41 ± 3.79c 6.04 ± 0.57a
16.32 ± 2.51b 4.47 ± 0.33ab
17.82 ± 2.37b 4.56 ± 0.42ab
17.40 ± 2.25b 4.36 ± 0.39ab
in the same column differ significantly (p < 0.05) by the Tukey HSD test.
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creased liver wet weights by 25.79% and 20.48%, respect-
ively, when compared to the HFC-control group, and the
results were comparable to those of rats treated with rosu-
vastatin. Rats of the HFC-control group also displayed the
highest relative liver weights. Although the relative liver
weights of rats treated with RYR extract and rosuvastatin
were not significantly different from those of the HFC-
control group, a slight decrease in relative liver weights
was observed. However, both liver wet weights and rela-
tive liver weights of normal rats treated with RYR extract
(SP-2 g) were not significantly different from those of rats
in the SP-control group.Effect of RYR administration on serum cholesterol
The serum cholesterol, including total cholesterol (TC),
HDL-cholesterol, and LDL-cholesterol of rats in all
groups are summarized in the Table 3.
The concentration of serum TC of rats in the HFC-
control group was significantly higher than those in the
SP-control group, by 101.38% (p < 0.05). RYR extract at
doses of 1.0 g/kg/day, 2.0 g/kg/day and rosuvastatin
could significantly decrease TC concentrations by
31.56%, 36.37% and 43.06%, respectively, when com-
pared to the HFC-control group (p < 0.05). Although the
concentrations of serum TC of hypercholesterolemic
rats treated with RYR extract at the dose of 2.0 g/kg/day
and rosuvastatin were slightly higher than those of nor-
mocholesterolemic rats (SP-groups), the statistical differ-
ences between those three groups were not evidenced.
The HDL-C concentrations of rats in all groups
remained at similar levels, while the LDL-C concentra-
tion in the HFC-control became significantly higher than
that of the SP-control group (p < 0.05). LDL-C levels of
hypercholesterolemic rats administered with RYR extract
at doses of 1.0 g/kg/day and 2.0 g/kg/day were, however,
significantly lower than those of HFC-control group by
37.42% and 47.37%, respectively (p < 0.05). The hypocho-
lesterolemic effect of RYR extract was found to be com-





SP-control 74.63 ± 11.31a 53.38 ± 7.78a
SP-2 g 74.00 ± 10.73a 52.13 ± 6.66a
HFC-control 150.29 ± 20.51c 48.00 ± 8.41a
HFC-1 g 102.86 ± 22.22b 54.43 ± 7.55a
HFC-2 g 95.63 ± 19.98ab 51.63 ± 7.95a
HFC-rosuvastatin 85.57 ± 16.23ab 50.29 ± 9.91a
Each value is the mean ± SD (n = 8). Values with different superscript letters (a,b,c)
HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesteThe normal rats treated with RYR 2.0 g/kg/day (SP-2 g)
presented similar concentrations of all serum cholesterol,
to those of normal control rats fed with a SP-diet (SP-
control).
Effect of RYR administration on atherosclerotic index and
LDL-C/HDL-C ratio
The atherosclerotic index (AI) is an index used to predict
the risk of atherosclerosis in hypercholesterolemic pa-
tients, and is expressed by the ratio (TC-HDL-C)/HDL-C.
It was found that the AI of hypercholesterolemic rats in
the HFC-1 g, HFC-2 g and HFC-rosuvastatin groups were
all reduced by approximately 60.63%, 61.99% and 67.87%,
respectively (p < 0.05), when compared to the HFC-
control group. Similarly, rats treated with RYR extract at
both doses used, and with rosuvastatin, displayed a signifi-
cantly lower LDL-C/HDL-C ratio, a predictive indicator of
cardiovascular diseases than the HFC-control group, by
45.96%, 52.41% and 68.54%, respectively (p < 0.05). The AI
and LDL-C/HDL-C ratio of normocholesterolemic rats in
both the SP-control and SP-2 g groups were extremely
low, and no difference in both indices was observed be-
tween these 2 groups (Table 3).
Effect of RYR administration on hepatic mRNA
expressions
The mRNA expressions of cholesterol homeostasis,
including CYP7A1, the LDL receptor and HMG-CoA
reductase in hypercholesterolemic rats are presented in
Figure 1. The mRNA expression of CYP7A1 of hyper-
cholesterolemic rats in all groups was higher than that
of SP-control rats. Nevertheless, significant decrease of
CYP7A1 expression (p < 0.05) was observed in hyper-
cholesterolemic rats treated with RYR, (HFC-1 g and
HFC-2 g) and rosuvastatin (HFC-rosuvastatin). The
mRNA expression of the LDL receptors in the HFC-
control group was, remarkably, the lowest, whereas in
the HFC-2 g and HFC-rosuvastatin groups it was signifi-
cantly higher than in the HFC-control group (p < 0.05).
Likewise, the mRNA expression of HMG-CoA reductase





4.25 ± 3.11a 0.40 ± 0.06a 0.08 ± 0.01a
3.50 ± 2.00a 0.42 ± 0.04ab 0.07 ± 0.04ab
58.67 ± 7.76d 2.13 ± 0.71c 1.22 ± 0.15c
36.71 ± 9.69c 0.89 ± 0.19b 0.67 ± 0.12b
30.88 ± 12.10bc 0.85 ± 0.18ab 0.60 ± 0.18ab
19.71 ± 5.91b 0.70 ± 0.10ab 0.39 ± 0.10ab
in the same column differ significantly (p < 0.05) by the Tukey HSD test.
rol.
Figure 1 Hepatic mRNA expressions of cholesterol metabolism-related genes. Hepatic cholesterol 7 alpha-hydroxylase (CYP7A1) (A), LDL
receptor (B), and HMG-CoA reductase (C) in male rats, fed with SP-diet and HFC-diet with red yeast rice extract and rosuvastatin for 30 days.
Values were normalized to reference gene GAPDH, and are expressed relative to the control level (SP-control). Data are expressed as mean ±
standard deviation (SD) (n = 8). Each value is the mean ± SD (n = 8). Values with different superscript letters (a,b,c) in the each column differ
significantly (p < 0.05) by the Tukey HSD test.
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2 g could significantly increase the expression of HMG-
CoA reductase when compared with HFC-control group
(p < 0.05), while rosuvastatin did not show this result.
No significant difference in all mRNA expressions was
observed between the SP-control and SP-2 g groups.
Effect of RYR administration on hepatic lipids
The lipid accumulations in the livers of the SP-diet and
HFC-diet fed rats were investigated, by measuring the
liver total lipid (TL) and total cholesterol (TC) levels, as
shown in Table 4. The TL and TC levels of the HFC-diet
fed rats were significantly higher than those of the
normal rats fed with a SP-diet. RYR extract at doses of
1.0 g/kg/day and 2.0 g/kg/day and rosuvastatin could
significantly decrease liver TL concentrations of hyper-
cholesterolemic rats by 26.81%, 28.05% and 27.49%,
respectively and decrease liver TC concentrations by
31.22%, 50.86% and 35.26%, respectively (p < 0.05), when
compared to the HFC-control group. Moreover, TC con-
centrations of hypercholesterolemic rats treated with
RYR extract and rosuvastatin were comparable to those




Hepatic lipid (mg/g liver)
Total lipid Total cholesterol
SP-control 41.16 ± 6.75a 6.00 ± 0.95a
SP-2 g 38.40 ± 5.34a 5.44 ± 0.89a
HFC-control 187.09 ± 5.84c 9.20 ± 0.50b
HFC-1 g 136.93 ± 12.93b 6.33 ± 1.66a
HFC-2 g 134.60 ± 9.89b 4.52 ± 1.96a
HFC-rosuvastatin 135.66 ± 11.75b 5.96 ± 1.68a
Each value is the mean ± SD (n = 8). Values with different superscript letters
(a,b,c) in the same column differ significantly (p < 0.05) by the Tukey HSD test.Effect of RYR administration on macroscopic and
microscopic structures of the liver
Gross observation revealed that all hypercholesterolemic
rats had developed fatty livers. The liver sizes of all rats
fed with a high-fat and cholesterol diet were larger than
those of normal rats fed with an SP-diet, and they also
became yellow-brown. The liver sizes of hypercholesterol-
emic rats treated with RYR extract and rosuvastatin were
equal to those of the normal control rats (SP-control).
The liver sizes and colors of the normal rats treated with
RYR extract (SP-2 g) were not different from those of the
normal control rats (SP-control) (Figure 2).
Microscopically, fat droplets were found deposited
in the hepatocytes of all rats fed with an HFC-diet. In
the HFC-control group, the presence of steatosis with
inflammatory cell infiltrations and nuclear condensation
was observed in the large area of acinar zone 3 of
the liver, while the HFC-1 g group showed a moderate
amount of steatosis, with inflammatory cell infiltrations
in the small area of acinar zone 3. The livers of the
HFC-2 g and HFC-rosuvastatin groups displayed steato-
sis with inflammatory cell infiltrations to a much lesser
extent than the HFC-control and HFC-1 g groups, with
most of the nucleus remaining centrally located. Fur-
thermore, in the livers of rats fed on a SP-diet (SP-con-
trol and SP-2 g) the morphology of hepatocytes still
displayed normal architecture around the central veins,
still arranged in cords. No sign of a liver displaying both
steatosis and hepatitis was observed (Figure 3).
Discussion
RYR is not only valued for cuisine in China and East
Asia, it is also used in traditional medicine to improve
digestion, spleen function, blood circulation and to re-
solve blood stasis. RYR contains many compounds
which are believed to help lower blood lipid levels.
Those compounds include: monacolin (mainly HMG-
Figure 2 Macroscopic photo of liver. Livers of normal rats treated with distilled water (A) and 2.0 g/kg/day of RYR extract (B), and livers of
hypercholesterolemic rats treated with distilled water (C), 1.0 g/kg/day of RYR extract (D), 2.0 g/kg/day of RYR extract (E) and 5.0 mg/kg/day of
rosuvastatin (F), for 30 days.
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acid, linoleic acid, oleic acid and stearic acid [11,16]. Al-
though the hypolipidemic effects of RYR extract have
been well documented, there have been insufficient re-
ports about RYR from local Thai rice. In this study, we
demonstrate the potential of Thai RYR to reduce serum
cholesterol levels, when produced by fermentation of
Thai glutinous rice (Oryza sativa L. var. Niaw San-pah-
tawng) by Monascus purpureus CMU 002U.
Hypercholesterolemia could be in both inherited and
non-inherited forms. Familial hypercholesterolemia, a
genetic disorder caused by the mutations of genes that
encode LDL receptor, occurs less common than the
non-inherited form [2,7]. Due to the worldwide increase
in incidence of diet-induced hypercholesterolemia, we
decided to test the efficacy of Thai RYR extract in diet-
induced hypercholesterolemia Wistar rats. The similarities
between Wistar rat and human in the aspects of physiology
and metabolism make this species the promising animal
models for several metabolic syndromes, including hyper-
lipidemia and hypercholesterolemia [10,30,31]. Using high-
fat cholesterol diets to induce hypercholesterolemia in rats
is a popular and successful method much used in research,
and was also used in this study. It led to enhanced serum
TC and LDL-C levels in the HFC-control group, measured
at 150.29 mg/dl and 74.63 mg/dl, respectively. This indi-
cates that the HFC-diet had successfully induced hyper-
cholesterolemia in the rats in this study. In reference toour results, the major change observed in our experiment
was the reduction of serum TC and LDL-C levels in
rats fed with RYR 1.0 and 2.0 g/kg/day. The serum TC
decreased by 31.55% and 36.36%, LDL-C decreased by
37.42% and 47.36% in the HFC-1 g and HFC-2 g groups,
respectively, compared with the HFC-control group
(150.29 mg/dl in TC and 58.67 mg/dl in LDL-C). These
were confirmed by the positive control group (HFC-rosu-
vastatin), in which the serum TC and LDL-C were de-
creased from the HFC-control group by 43.06% and
66.40%, respectively.
According to a previous study, in which RYR was ad-
ministered to rabbits for 200 days, the serum TC was
25% and 40% lower in the rabbits fed with 0.4 g/kg/day
or 1.35 g/kg/day of red yeast rice, respectively, and there
was also lower levels of serum LDL-C and triglyceride
[12]. Additionally, upon examination of Chinese RYR
consumption (2.4 g/day) in an American population
with hypercholesterolemia, the serum TC concentration
decreased from 254.0 mg/dl to 208.0 mg/dl in 8 weeks,
and LDL-C and TG levels also decreased [23]. When In-
dian RYR was evaluated in rat models by administering
RYR at doses of 1.2 mg/kg and 2.4 mg/kg/day to the rats
for 30 days, the extract at both doses could maintain the
lipid profile (TC, TG, HDL, LDL-C and VLDL-C) of the
rats at near normal status [30]. Also, the administration
of RYR extract at doses of 0.4 g/kg/day and 0.8 g/kg/day
to the rabbits for 30 days could significantly lower their
Figure 3 Microscopic characters of liver tissue. Liver tissue of normal rats treated with distilled water (A) and 2.0 g/kg/day of RYR extract (B),
and liver tissue from hypercholesterolemic rats treated with 5.0 mg/kg/day of rosuvastatin (C), distilled water (D, G), 1.0 g/kg/day of RYR extract (E, H),
and 2.0 g/kg/day of RYR extract (F, I). Original magnifications were 100x (A-F) and 200x (G-I). Lipid deposition in hepatocyte (steatosis) (arrow),
steatosis with inflammatory cell infiltrations (steatosis hepatitis) (quadrilateral) and nuclear condensation (head arrow) were observed in the liver of
hypercholesterolemic rats (D-I). No remarkable damage was detected in SP and SP-2 g (A, B). CV, central vein; HC, hepatic cord (H & E).
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unclear that which substance(s) take the major role in
lowering cholesterol level, either only monacolin K or a
combination of monacolin K with other substances [11].
However, many researchers have succeeded in using
RYR to lower lipid levels in animal models and humans,
due to the presence of the same cholesterol synthesis in-
hibitor, monacolin K [17,32]. A liver cholesterol biosyn-
thetic pathway started with HMG-CoA reductase, an
enzyme that catalyzes the conversion of HMG-CoA to
mevalonate [33], which is the first key chemical in the
biosynthetic pathway leading to cholesterol as the final
product. Mevalonate activity is reduced by the inhibitor
known as the HMG-CoA reductase inhibitor or mona-
colin K, a substance found in RYR. This is the specific
inhibitor in the reaction of HMG-CoA reductase be-
cause monacolin K has the same chemical structure asthe ‘statin drugs’, a group of drugs used in hypercholester-
olemia treatment and potent inhibitors of 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase [34].
Indeed, the target of hypercholesterolemic therapies is
a reduction of the atherosclerotic index value and the
LDL-C/HDL-C ratios, along with a decrease of the
major lipids, which are key risk factors for cardiovascu-
lar disease, particularly total cholesterol and LDL-C [26].
This is consistent with the obtained data. The HFC-
control group in this experiment had a higher risk of
atherosclerosis and cardiovascular diseases than any
other group. Furthermore, in the rats treated with RYR
the index value of both doses decreased, such that the
results of the primary prevention trials with RYR have
demonstrated that lowering serum cholesterol and LDL-
C cholesterol can significantly reduce the risk of cardio-
vascular events [35,36].
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organ responsible for cholesterol homeostasis mainten-
ance, by regulating cholesterol synthesis and uptake as
well as cholesterol excretion into bile acids [37]. Gene
regulation mechanism implicated in cholesterol homeo-
stasis has been well-documented and the three genes,
HMG-CoA reductase, LDL receptor and CYP71, were
proposed as the key genes for the synthesis, absorption
and degradation of hepatic cholesterol, respectively. The
decrease of mRNA expression of HMG-CoA reductase
and LDL receptor and the increase of that of CYP71
were found in animals with high level of plasma choles-
terol condition [10,38,39]. The results of mRNA expres-
sion of HMG-CoA reductase, LDL receptor and CYP71
in diet-induced hypercholesterolemic rats (HFC-control
group) which correlated with the reports of the previous
study could support the importance of those 3 genes in
cholesterol homeostasis. Attempts have been made to
explore the molecular mechanism(s) underlying the ef-
fect of cholesterol lowering agents and different results
have been obtained from different researches [26,40].
Those different results indicated the different mecha-
nisms of their hypocholesterolemic effect. In this study,
the ability of RYR extract at 2.0 g/kg/day to enhance
mRNA expression of HMG-CoA reductase and LDL re-
ceptor reflect its potential to adjust the rate of choles-
terol synthesis and absorption. HMG-CoA reductase is
the regulatory enzyme of hepatic cholesterol biosyn-
thesis. The enzyme levels are suppressed by exogenous
cholesterol and degradation of low density lipoproteins
(LDL-C) via the up-regulation of the LDL receptor [31].
CYP7A1 is a gene involved in the biosynthetic pathway
of bile acids from cholesterol in liver for excretion into
bile [41]. Kawakami et al. [42] reported that the in-
creased expression of CYP7A1 is the mechanism of
hypocholesterolemic action that promoted excretion of
cholesterol and bile acids. In the present study, the
mRNA expressions of CYP7A1 of diet-induced hyper-
cholesterolemic rats treated with RYR extract and rosu-
vastatin were lower than those of HFC-control group.
This result is not consistent with previous studies, which
showed that the expression of CYP7A1 were up-
regulated in rats treated with puerarin [40]. The down
regulation of CYP7A1 expression by RYR extract implied
that cholesterol excretion was not the mechanism for its
hypocholesterolemic effect. Therefore, the decreasing of
blood cholesterol concentration by RYR extract was likely
to be due to its ability to promote the biosynthesis and ab-
sorption of blood cholesterol by increasing the hepatic
HMG-CoA reductase and LDL receptor expression.
In addition, this study clearly showed that the liver
weights of all HFC-diet fed rats (HFC-control, HFC-1 g,
HFC-2 g, HFC-rosuvastatin) were significantly higher
than those of SP-diet fed rats (SP-control and SP-2 g).Our data exhibited that in rats fed only an HFC-diet and
treated with RYR extract, at 1.0 g/kg/day and 2.0 g/kg/
day, their liver weight decreased by 25.79% and 20.48%,
respectively. The liver weight results were consistent
with the concentrations of lipid in the liver. The HFC-
control group had the highest TC concentrations com-
pared to all groups, significantly higher than those of
rats treated with RYR 1.0 g/kg/day and 2.0 g/kg/day.
The results indicated that high lipid and cholesterol
foods led to the development of hepatic steatosis condi-
tions, or fatty liver [43], where the hepatocyte is in re-
tention of fat within the cell. The imbalance between
acquisition by uptake of non-esterified fatty acids from
the plasma and by de novo lipogenesis and triglyceride
disposal by fatty acid oxidation and by the secretion of
triglyceride-rich lipoproteins was suggested as the mech-
anism underlying lipid accumulation in hepatocytes [44].
The result of hepatic lipid accumulation can be con-
firmed by microscopic images of the liver in Figure 3.
These images display the large vacuoles of fat accumu-
lated within hepatocytes (steatosis), and inflammatory
cell infiltrations that were observed in the HFC-diet fed
rats. The large area of steatosis with inflammatory cell
infiltrations was observed in all HFC-diet fed rats, espe-
cially in the HFC-control group (Figure 3D,G). Never-
theless, HFC-diet fed rats treated with RYR at 1.0 and
2.0 g/kg/day exhibited a smaller area of steatosis with
inflammatory cells than the HFC-control group. Interest-
ingly, the capacity of the extract at the dose of 2.0 g/kg/
day to reduce liver steatosis was nearly comparable to
rosuvastatin, a synthetic hypocholesterolemic drug. When
this steatosis becomes associated with inflammation, it is
called steatosis hepatitis, and forms chronic liver disease
[45]. This feature can be classified histologically, by lesions
that differ from the steatosis and inflammation, into 3
types: type 1 (mild) the amount of steatosis and inflamma-
tion is less than 33% in the acinar zone 3 area: type 2
(moderate) is observed at 33%-66%: and more than 66% is
type 3 (severe) steatosis [46,47]. According to this classifi-
cation, the livers of the HFC-control group were already
classified as types 3, while the hypercholesterolemic rats
treated with RYR 1.0 g/kg/day and 2.0 g/kg/day were
already classified as types 2 and 1, respectively. From our
findings, the extract of Thai RYR can help reduce the de-
velopment of severe steatosis and chronic liver disease.
Conclusion
The experimental data suggest that Thai RYR, Thai glu-
tinous rice fermented by Monascus purpureus CMU
002U, could potentially decrease serum total cholesterol
and LDL-C levels, and also reduce atherosclerosis and
cardiovascular diseases. Furthermore, this RYR could de-
crease lipid accumulation in the liver, thereby delaying
the onset of hepatic steatosis. The success of this study
Bunnoy et al. BMC Complementary and Alternative Medicine  (2015) 15:88 Page 10 of 11could lead to future research for developing cholesterol
lowering products from a local rice of Thailand.
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